Determinants of outcome in patients eligible for thrombolysis for ischemic stroke
Eligibility criteria for thrombolysis in ischemic stroke have been clearly defined. However, not all eligible patients benefit from this treatment. This study aimed to assess the determinants for clinical outcome in consecutive, eligible patients with ischemic stroke treated with thrombolysis in a s...
Saved in:
| Published in | Vascular health and risk management Vol. 3; no. 5; pp. 749 - 754 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New Zealand
Taylor & Francis Ltd
2007
Dove Medical Press |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Eligibility criteria for thrombolysis in ischemic stroke have been clearly defined. However, not all eligible patients benefit from this treatment. This study aimed to assess the determinants for clinical outcome in consecutive, eligible patients with ischemic stroke treated with thrombolysis in a single-center study.
Consecutive patients with ischemic stroke were treated with tissue plasminogen activator (t-PA) following the established eligibility National Institute of Neurological Disorders and Stroke (NINDS) and European Stroke Initiative (EUSI) criteria. Risk factors including blood pressure and pre-treatment glycemia were properly managed. Death and disability at 3 months were the study outcomes. Disability was evaluated by the Rankin-scale. Favorable outcome was defined as 0-2 and adverse outcome as 3-6 including death.
Seventy-eight patients were included in the study in a single stroke unit. The mean age was 70.9 +/- 13.2 years (range 36-94). Follow-up at 3 months was completed in 73 patients. A favorable outcome was observed in 37 patients (50%) and adverse outcome in 36 (36%). Nine patients (12.3%) died within 3 months. The presence of an occluded carotid artery was a strong predictor for adverse outcome (p < 0.0001). A low NIH Stroke Scale-Score (NIHSS) at admission was a associated with a favorable outcome, while history of diabetes mellitus led to an unfavorable outcome.
Among patients eligible for thrombolysis, many do not benefit from this treatment. These include patients with carotid occlusion and diabetes. |
|---|---|
| AbstractList | Objectives:Eligibility criteria for thrombolysis in ischemic stroke have been clearly defined. However, not all eligible patients benefit from this treatment. This study aimed to assess the determinants for clinical outcome in consecutive, eligible patients with ischemic stroke treated with thrombolysis in a single-center study. Methods: Consecutive patients with ischemic stroke were treated with tissue plasminogen activator (t-PA) following the established eligibility National Institute of Neurological Disorders and Stroke (NINDS) and European Stroke Initiative (EUSI) criteria. Risk factors including blood pressure and pre-treatment glycemia were properly managed. Death and disability at 3 months were the study outcomes. Disability was evaluated by the Rankin-scale. Favorable outcome was defined as 0–2 and adverse outcome as 3–6 including death. Results: Seventy-eight patients were included in the study in a single stroke unit. The mean age was 70.9 ± 13.2 years (range 36–94). Follow-up at 3 months was completed in 73 patients. A favorable outcome was observed in 37 patients (50%) and adverse outcome in 36 (36%). Nine patients (12.3%) died within 3 months. The presence of an occluded carotid artery was a strong predictor for adverse outcome (p > 0.0001). A low NIH Stroke Scale-Score (NIHSS) at admission was a associated with a favorable outcome, while history of diabetes mellitus led to an unfavorable outcome. Conclusion: Among patients eligible for thrombolysis, many do not benefit from this treatment. These include patients with carotid occlusion and diabetes. Eligibility criteria for thrombolysis in ischemic stroke have been clearly defined. However, not all eligible patients benefit from this treatment. This study aimed to assess the determinants for clinical outcome in consecutive, eligible patients with ischemic stroke treated with thrombolysis in a single-center study. Consecutive patients with ischemic stroke were treated with tissue plasminogen activator (t-PA) following the established eligibility National Institute of Neurological Disorders and Stroke (NINDS) and European Stroke Initiative (EUSI) criteria. Risk factors including blood pressure and pre-treatment glycemia were properly managed. Death and disability at 3 months were the study outcomes. Disability was evaluated by the Rankin-scale. Favorable outcome was defined as 0-2 and adverse outcome as 3-6 including death. Seventy-eight patients were included in the study in a single stroke unit. The mean age was 70.9 +/- 13.2 years (range 36-94). Follow-up at 3 months was completed in 73 patients. A favorable outcome was observed in 37 patients (50%) and adverse outcome in 36 (36%). Nine patients (12.3%) died within 3 months. The presence of an occluded carotid artery was a strong predictor for adverse outcome (p < 0.0001). A low NIH Stroke Scale-Score (NIHSS) at admission was a associated with a favorable outcome, while history of diabetes mellitus led to an unfavorable outcome. Among patients eligible for thrombolysis, many do not benefit from this treatment. These include patients with carotid occlusion and diabetes. OBJECTIVESEligibility criteria for thrombolysis in ischemic stroke have been clearly defined. However, not all eligible patients benefit from this treatment. This study aimed to assess the determinants for clinical outcome in consecutive, eligible patients with ischemic stroke treated with thrombolysis in a single-center study. METHODSConsecutive patients with ischemic stroke were treated with tissue plasminogen activator (t-PA) following the established eligibility National Institute of Neurological Disorders and Stroke (NINDS) and European Stroke Initiative (EUSI) criteria. Risk factors including blood pressure and pre-treatment glycemia were properly managed. Death and disability at 3 months were the study outcomes. Disability was evaluated by the Rankin-scale. Favorable outcome was defined as 0-2 and adverse outcome as 3-6 including death. RESULTSSeventy-eight patients were included in the study in a single stroke unit. The mean age was 70.9 +/- 13.2 years (range 36-94). Follow-up at 3 months was completed in 73 patients. A favorable outcome was observed in 37 patients (50%) and adverse outcome in 36 (36%). Nine patients (12.3%) died within 3 months. The presence of an occluded carotid artery was a strong predictor for adverse outcome (p < 0.0001). A low NIH Stroke Scale-Score (NIHSS) at admission was a associated with a favorable outcome, while history of diabetes mellitus led to an unfavorable outcome. CONCLUSIONAmong patients eligible for thrombolysis, many do not benefit from this treatment. These include patients with carotid occlusion and diabetes. Valeria Caso, Maurizio Paciaroni, Michele Venti, Francesco Palmerini, Giorgio Silvestrelli, Paolo Milia, Sergio Biagini, Giancarlo AgnelliStroke Unit, Department of Internal Medicine, Ospedale Silvestrini Perugia, ItalyObjectives: Eligibility criteria for thrombolysis in ischemic stroke have been clearly defined. However, not all eligible patients benefit from this treatment. This study aimed to assess the determinants for clinical outcome in consecutive, eligible patients with ischemic stroke treated with thrombolysis in a single-center study.Methods: Consecutive patients with ischemic stroke were treated with tissue plasminogen activator (t-PA) following the established eligibility National Institute of Neurological Disorders and Stroke (NINDS) and European Stroke Initiative (EUSI) criteria. Risk factors including blood pressure and pre-treatment glycemia were properly managed. Death and disability at 3 months were the study outcomes. Disability was evaluated by the Rankin-scale. Favorable outcome was defined as 0-2 and adverse outcome as 3-6 including death.Results: Seventy-eight patients were included in the study in a single stroke unit. The mean age was 70.9 ± 13.2 years (range 36-94). Follow-up at 3 months was completed in 73 patients. A favorable outcome was observed in 37 patients (50%) and adverse outcome in 36 (36%). Nine patients (12.3%) died within 3 months. The presence of an occluded carotid artery was a strong predictor for adverse outcome (p> 0.0001). A low NIH Stroke Scale-Score (NIHSS) at admission was a associated with a favorable outcome, while history of diabetes mellitus led to an unfavorable outcome.Conclusion: Among patients eligible for thrombolysis, many do not benefit from this treatment. These include patients with carotid occlusion and diabetes.Keywords: thrombolysis, stroke, outcome, diabetes, carotid artery occlusion Objectives Eligibility criteria for thrombolysis in ischemic stroke have been clearly defined. However, not all eligible patients benefit from this treatment. This study aimed to assess the determinants for clinical outcome in consecutive, eligible patients with ischemic stroke treated with thrombolysis in a single-center study. Methods Consecutive patients with ischemic stroke were treated with tissue plasminogen activator (t-PA) following the established eligibility National Institute of Neurological Disorders and Stroke (NINDS) and European Stroke Initiative (EUSI) criteria. Risk factors including blood pressure and pre-treatment glycemia were properly managed. Death and disability at 3 months were the study outcomes. Disability was evaluated by the Rankin-scale. Favorable outcome was defined as 0a2 and adverse outcome as 3a6 including death. Results Seventy-eight patients were included in the study in a single stroke unit. The mean age was 70.9 A- 13.2 years (range 36a94). Follow-up at 3 months was completed in 73 patients. A favorable outcome was observed in 37 patients (50%) and adverse outcome in 36 (36%). Nine patients (12.3%) died within 3 months. The presence of an occluded carotid artery was a strong predictor for adverse outcome (p & 0.0001). A low NIH Stroke Scale-Score (NIHSS) at admission was a associated with a favorable outcome, while history of diabetes mellitus led to an unfavorable outcome. Conclusion Among patients eligible for thrombolysis, many do not benefit from this treatment. These include patients with carotid occlusion and diabetes. |
| Author | Agnelli, Giancarlo Silvestrelli, Giorgio Venti, Michele Paciaroni, Maurizio Milia, Paolo Palmerini, Francesco Caso, Valeria Biagini, Sergio |
| Author_xml | – sequence: 1 givenname: Valeria surname: Caso fullname: Caso, Valeria email: vcaso@hotmail.com organization: Stroke Unit, Department of Internal Medicine, Ospedale Silvestrini Perugia, Italy. vcaso@hotmail.com – sequence: 2 givenname: Maurizio surname: Paciaroni fullname: Paciaroni, Maurizio – sequence: 3 givenname: Michele surname: Venti fullname: Venti, Michele – sequence: 4 givenname: Francesco surname: Palmerini fullname: Palmerini, Francesco – sequence: 5 givenname: Giorgio surname: Silvestrelli fullname: Silvestrelli, Giorgio – sequence: 6 givenname: Paolo surname: Milia fullname: Milia, Paolo – sequence: 7 givenname: Sergio surname: Biagini fullname: Biagini, Sergio – sequence: 8 givenname: Giancarlo surname: Agnelli fullname: Agnelli, Giancarlo |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/18078026$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUtr3TAQhU1JyKv5C8UQ6M4wkixZ2gRC-goEQiFdC1ke3asb27qR5EL-fZWbB0k23UjizOGbM6Pjam8OM36qjgjpZEOhlXu7t2gEa9vD6jilDQAXEshBdUgkdBKoOKp-f8OMcfKzmXOqg6vDkm2YsPZzvTXZ46OMo1_5fsTahVjndQxTH8aH5NNO8MmucfK2TjmGO_xc7TszJjx9vk-qPz--317-aq5vfl5dXlw3A5MqN6x1iFJSKzgjikoOSlLVUoBeUMacHQi4Xhg5dAQ67Ig1OHAHxlkLVlJ2Ul09cYdgNnob_WTigw7G650Q4kqbmL0dUQuHBm1vFbW25QTMYDixihh0ygopCuv8ibVd-gkHW6aOZnwHfV-Z_Vqvwl9NqSIlfgF8fQbEcL9gynoqa8FxNDOGJWmhQNBy_NdIQSjOBSvGsw_GTVjiXDZampa2nAE8ur68Df6a-OWD2T8xxaXr |
| ContentType | Journal Article |
| Copyright | Copyright Taylor & Francis Ltd. 2007 2007 Dove Medical Press Limited. All rights reserved 2007 |
| Copyright_xml | – notice: Copyright Taylor & Francis Ltd. 2007 – notice: 2007 Dove Medical Press Limited. All rights reserved 2007 |
| DBID | CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88C 8AO 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. KB0 M0S M0T M2O MBDVC NAPCQ PIMPY PQEST PQQKQ PQUKI PRINS Q9U 7TK 7U1 7U2 C1K 7X8 5PM DOA |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Nursing and Allied Health Journals Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Health Management Database (Proquest) ProQuest Research Library Research Library (Corporate) Nursing & Allied Health Premium Access via ProQuest (Open Access) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic Neurosciences Abstracts Risk Abstracts Safety Science and Risk Environmental Sciences and Pollution Management MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Research Library ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) Risk Abstracts Safety Science and Risk Neurosciences Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic Risk Abstracts |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1178-2048 |
| EndPage | 754 |
| ExternalDocumentID | oai_doaj_org_article_6feaecbc92cc4510ada51c91aef9c686 18078026 |
| Genre | Journal Article |
| GroupedDBID | --- 04C 0YH 123 29Q 2WC 53G 5VS 6PF 7RV 7X7 8AO 8FI 8FJ 8G5 AAWTL ABUWG ACGFO ADBBV ADRAZ AFKRA AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AQUVI AZQEC BAWUL BCNDV BENPR BKEYQ BMSDO BPHCQ BVXVI CCPQU CGR CS3 CUY CVF DIK DU5 DWQXO E3Z EBD EBS ECM EIF EIHBH EJD F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HMCUK HYE IAO IHR IHW INH INR IPNFZ ITC KQ8 M0T M2O M48 M~E NAPCQ NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC RIG RNS RPM TR2 UKHRP VDV 3V. 7XB 8FK K9. MBDVC PQEST PQUKI PRINS Q9U 7TK 7U1 7U2 C1K 7X8 5PM |
| ID | FETCH-LOGICAL-d389t-34fee882c65319285098294200b6233fcd10fb6a8d7107e71caed5f0afcc0c823 |
| IEDL.DBID | RPM |
| ISSN | 1176-6344 1178-2048 |
| IngestDate | Tue Oct 22 15:16:19 EDT 2024 Tue Sep 17 21:26:39 EDT 2024 Fri Oct 25 22:51:09 EDT 2024 Sun Sep 29 07:40:34 EDT 2024 Thu Oct 10 20:34:04 EDT 2024 Sat Sep 28 07:51:08 EDT 2024 |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-d389t-34fee882c65319285098294200b6233fcd10fb6a8d7107e71caed5f0afcc0c823 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291319/ |
| PMID | 18078026 |
| PQID | 2222953003 |
| PQPubID | 3933269 |
| PageCount | 6 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6feaecbc92cc4510ada51c91aef9c686 pubmedcentral_primary_oai_pubmedcentral_nih_gov_2291319 proquest_miscellaneous_69062690 proquest_miscellaneous_20695563 proquest_journals_2222953003 pubmed_primary_18078026 |
| PublicationCentury | 2000 |
| PublicationDate | 2007-00-00 |
| PublicationDateYYYYMMDD | 2007-01-01 |
| PublicationDate_xml | – year: 2007 text: 2007-00-00 |
| PublicationDecade | 2000 |
| PublicationPlace | New Zealand |
| PublicationPlace_xml | – name: New Zealand – name: Macclesfield |
| PublicationTitle | Vascular health and risk management |
| PublicationTitleAlternate | Vasc Health Risk Manag |
| PublicationYear | 2007 |
| Publisher | Taylor & Francis Ltd Dove Medical Press |
| Publisher_xml | – name: Taylor & Francis Ltd – name: Dove Medical Press |
| References | 10703776 - JAMA. 2000 Mar 1;283(9):1145-50 9707190 - Stroke. 1998 Aug;29(8):1544-9 11502916 - Neurology. 2001 Aug 14;57(3):474-80 12855832 - Stroke. 2003 Aug;34(8):1833-40 10209350 - Eur J Neurol. 1999 Jan;6(1):51-5 10532643 - Neurology. 1999;53(7 Suppl 4):S3-14 16505004 - J Neurol Neurosurg Psychiatry. 2006 Jul;77(7):826-9 12221155 - Neurology. 2002 Sep 10;59(5):669-74 15883405 - CMAJ. 2005 May 10;172(10):1307-12 10971019 - Cerebrovasc Dis. 2000 Sep-Oct;10(5):335-51 2727536 - Rev Neurol (Paris). 1989;145(2):134-9 2730378 - Arch Neurol. 1989 Jun;46(6):660-2 11939889 - Arch Neurol. 2002 Apr;59(4):549-53 12140674 - J Neurol. 2002 Jul;249(7):888-95 11559501 - AJNR Am J Neuroradiol. 2001 Sep;22(8):1534-42 8929152 - Arch Neurol. 1996 Apr;53(4):309-15 10657408 - Stroke. 2000 Feb;31(2):370-5 7563451 - JAMA. 1995 Oct 4;274(13):1017-25 10591384 - JAMA. 1999 Dec 1;282(21):2019-26 11546993 - Crit Care Med. 2001 Sep;29(9):1812-8 15494581 - JAMA. 2004 Oct 20;292(15):1839-44 7886712 - Stroke. 1995 Mar;26(3):392-8 16107357 - J Neurol Neurosurg Psychiatry. 2005 Sep;76(9):1234-7 9836764 - Stroke. 1998 Dec;29(12):2529-40 1642475 - Ann Neurol. 1992 Jul;32(1):78-86 12154264 - Stroke. 2002 Aug;33(8):2066-71 1579252 - Neurology. 1992 May;42(5):976-82 7477192 - N Engl J Med. 1995 Dec 14;333(24):1581-7 10067786 - J Hypertens. 1999 Feb;17(2):151-83 15494580 - JAMA. 2004 Oct 20;292(15):1831-8 7678184 - Stroke. 1993 Jan;24(1):35-41 14584488 - Cerebrovasc Dis. 2003;16(4):311-37 3363593 - Stroke. 1988 May;19(5):604-7 15016487 - Lancet. 2004 Mar 6;363(9411):768-74 9788453 - Lancet. 1998 Oct 17;352(9136):1245-51 |
| References_xml | |
| SSID | ssj0056801 |
| Score | 1.8590199 |
| Snippet | Eligibility criteria for thrombolysis in ischemic stroke have been clearly defined. However, not all eligible patients benefit from this treatment. This study... Objectives:Eligibility criteria for thrombolysis in ischemic stroke have been clearly defined. However, not all eligible patients benefit from this treatment.... Objectives Eligibility criteria for thrombolysis in ischemic stroke have been clearly defined. However, not all eligible patients benefit from this treatment.... OBJECTIVESEligibility criteria for thrombolysis in ischemic stroke have been clearly defined. However, not all eligible patients benefit from this treatment.... Valeria Caso, Maurizio Paciaroni, Michele Venti, Francesco Palmerini, Giorgio Silvestrelli, Paolo Milia, Sergio Biagini, Giancarlo AgnelliStroke Unit,... |
| SourceID | doaj pubmedcentral proquest pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 749 |
| SubjectTerms | Adult Aged Aged, 80 and over Brain Ischemia - drug therapy Brain Ischemia - epidemiology Diabetes Female Humans Male Middle Aged Multivariate Analysis Original Research Risk Factors Stroke Stroke - drug therapy Stroke - epidemiology Thrombolytic Therapy Treatment Outcome |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA7iQbyIb6ur5uC12KRt2hx9LYugICjsreQxwUVtZbf7_52kVXZF8eKlhySFZGaSfJlMviHkTHCVaC5NXCD8jjNhcR1k1sTK6pw7C1mq_Wvku3sxespux_l4IdWXjwnr6IE7wZ0LBwqMNpIbk6EBKatyZiRT4KQRZUe2ncjPw1S3BueiDImPGSu8HfjkPoGR_ycY-T0acmF7GW6SjR4X0ouuP1tkBeptsnbX33zvkIfrhbgV2jjazFs0FqCTmvbcqDMawov1K1BEotQnQHjTTaAcCQUTPMj6UHg6a6fNC-ySp-HN49Uo7tMhxBZRRRunmQNAQGyEnze8xK2-5DJDM9eIYVJnLEucFqq0iBoKKJhRYHOXKGdMYkqe7pHVuqnhgFCFPxqVpFx5t09iFZNZyZXMtQFWgI3IpRdX9d4xXlSegzoUoGaqXjPVX5qJyOBT2FU_MWYVD_nDU1xLInL6VY0m7e8pVA3NHNskQnrest9bBHZl_ERkv9PdV0-Z58_Hc2VEiiWtLg1luaaePAdabewYQ8Ee_sfYj8h65wT2vpoBWW2nczhG9NLqk2CoH6r79H8 priority: 102 providerName: Directory of Open Access Journals – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BVkJcUMuroQ984BoRO46TnFCfqiq1AkSl3iI_xrAqJO1u9v8z9npLtwIuOdiOZHvG48_j8TcAH5TQhRGtzWuC37lUjuwgdzbXzlTCO5SlCa-RLy7V2ZU8v66uk8NtnsIqVzYxGmo32OAj_yhi4umSlPDT7V0eskaF29WUQuMpbAg6KYgJbByeXH7-urLFlWpiAmTOa5WrUsrEzP83OPk4KvLBNnO6CS8SPmQHS4FuwRPsX8Kzi3QD_gq-HD-IX2GDZ8NipAEgm_YscaTOWQwzNj-RESJlIRHCLzNE6pFYMKUDbQiJZ_NxNtzga7g6Pfl2dJantAi5I3Qx5qX0iASMrQrrRzS05TeilaTuhrBM6a3jhTdKN47QQ401txpd5QvtrS1sI8o3MOmHHreBafrR6qIUOrh_Cqd5Kxuh28pY5DW6DA7DdHW3S-aLLnBRx4Jh9r1Lqt0pjxqtsa2wVtIS105X3LZco2-talQGu6vJ7tICmXd_xJnB-_tqUu1wX6F7HBbUplBt4C_7d4vIskyfDN4uZXffUx549Ol8mUG9JtW1oazX9NMfkV6bOsZpYt_9v9s78Hzp5g3emF2YjLMF7hE-Gc1-UsLfCzDrTA priority: 102 providerName: ProQuest |
| Title | Determinants of outcome in patients eligible for thrombolysis for ischemic stroke |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/18078026 https://www.proquest.com/docview/2222953003 https://search.proquest.com/docview/20695563 https://search.proquest.com/docview/69062690 https://pubmed.ncbi.nlm.nih.gov/PMC2291319 https://doaj.org/article/6feaecbc92cc4510ada51c91aef9c686 |
| Volume | 3 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4BlapeqtJnCmx96DVs7DhOfAQKQpUW0apIe4v8bFewCdrN_v-OnQSxVblwycEPyfF8tj_b428AvgqmMs2kSUuk3ykXFudBak2qrC6Yt47nOrxGnl2Jyxv-fV7Md6AY38JEp32jF8fN3fK4WfyJvpX3SzMd_cSm17MzxiRF6Ex3YRcBOm7R--m3EFWMeUxpKVKR8xh4J4iqR_2EqMv_PzL5r0_ko0Xm4g28HtghOelbsQ87rnkLL2fD_fc7-PHtkfcKaT1pNx1CxpFFQwaF1DWJTsb6zhHkoySEQVjqNgqPxIQFbmeDQzxZd6v21r2Hm4vzX2eX6RAUIbXILbo05945pMVGhNHDKlzwKyY5gl0jk8m9sTTzWqjKIncoXUmNcrbwmfLGZKZi-QfYa9rGfQKisKJRWc5UOPzJrKKSV0zJQhtHS2cTOA3dVd_3uhd1UKKOCe3qdz3YoxbeKWe0kcwYjgNcWVVQI6lyXhpRiQQOx86uh-GxrlmMIp7jjJLAl4dsBHa4rVCNazdYJhMyqJc9XSJqLOMngY-97R5aOho8gXLLqlu_sp2DWIvi2gO2Pj-75gG86s9_wzHNIex1q407QuLS6QnCdV5O4MXp-dX1z0nc_uN3xqtJhPBf67b3RQ |
| link.rule.ids | 230,315,730,783,787,888,2109,2228,4033,12070,21402,31733,31734,33758,33759,43324,43819,53806,53808,74081,74638 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BkYBLVZ5NKdQHrhGx4zjJCfFotUC3ElIr7S3yY1xW0KTsZv8_Y6-7dBFwycF2pIlnbH-emXwD8FoJXRjR2rwm-J1L5Wgf5M7m2plKeIeyNOFv5OmZmlzIz7Nqlhxuy5RWebMnxo3aDTb4yN-IWHi6JCN8e_0zD1WjQnQ1ldC4C_cCD1fgzq9nmwtXpZpY_pjzWuWqlDLx8v8NTP6ZE3nrkDnZg92EDtm7tTofwR3sH8P9aYp_P4GvH29lr7DBs2E1kvjI5j1LDKlLFpOMzQ9khEdZKINwZYZIPBIb5nSdDQnxbDkuhu_4FC5Ojs8_TPJUFCF3hC3GvJQekWCxVWH1iIYO_Ea0kozdEJIpvXW88EbpxhF2qLHmVqOrfKG9tYVtRPkMdvqhx31gml60uiiFDs6fwmneykbotjIWeY0ug_dhurrrNe9FF5ioY8OwuOySYXfKo0ZrbCuslbTAtdMVty3X6FurGpXB4c1kd2l5LLvfyszgaNNNhh2iFbrHYUVjCtUG9rJ_j4gcy_TI4PladxtJeWDRp9tlBvWWVrc-Zbunn3-L5NokGKeJPfi_2EfwYHI-Pe1OP519eQEP1w7f4Jc5hJ1xscKXhFRG8yqa4y9TbOzX |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB6VVqq4ICivQKE-cI2IHcdJTggoq9KXQKLS3iI_xu2qkJTd7P9n7HWXLgIuOTiOZHvG9ufxl28A3iihCyNam9cEv3OpHK2D3NlcO1MJ71CWJvyNfHauji7k8bSaJv7TItEqb9fEuFC7wYYY-VsRE0-XIe7mEy3iy-Hk3c3PPGSQCjetKZ3GPdipJW105Nv1dH34qlQTUyFzXqtclVImjf6_Acs_-ZF3NpzJQ3iQkCJ7vzLtI9jCfg92z9Jd-GP4eniHycIGz4blSF1BNutZUktdsEg4Nt-RETZlISXCDzNEEZJYMKOjbSDHs8U4H67xCVxMPn37eJSnBAm5I5wx5qX0iASRrQozSTS0-TeileT4hlBN6a3jhTdKN45wRI01txpd5QvtrS1sI8qnsN0PPT4HpulDq4tS6BAIKpzmrWyEbitjkdfoMvgQhqu7WWlgdEGVOhYM88suOXmnPGq0xrbCWkmTXTtdcdtyjb61qlEZ7N8OdpemyqL7bdgMDtavycnDzYXucVhSnUK1Qcns3zWi3jI9Mni2st26pTwo6tNJM4N6w6obXdl808-uotA2NYzTwL74f7MPYJc8sTv9fH7yEu6vYr8hRLMP2-N8ia8ItIzmdfTGXw7Y8Qw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Determinants+of+outcome+in+patients+eligible+for+thrombolysis+for+ischemic+stroke&rft.jtitle=Vascular+health+and+risk+management&rft.au=Caso%2C+Valeria&rft.au=Paciaroni%2C+Maurizio&rft.au=Venti%2C+Michele&rft.au=Palmerini%2C+Francesco&rft.date=2007&rft.pub=Dove+Medical+Press&rft.issn=1176-6344&rft.eissn=1178-2048&rft.volume=3&rft.issue=5&rft.spage=749&rft.epage=754&rft_id=info%3Apmid%2F18078026&rft.externalDBID=PMC2291319 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1176-6344&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1176-6344&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1176-6344&client=summon |